Tickers

1. Composite Trajectory Verdict

The income statement matters most for assessing BBAI because its government-services-and-software business model is defined by contract execution, margin stability, and operating leverage -- not by financing-driven balance-sheet changes.

Composite Trajectory: Mixed

The income statement and cash flow statement show clear deterioration: revenue fell 19.3% year-over-year to $127.7M (10-K 2025, Consolidated Statements of Operations), gross margin compressed from 28.6% to 22.3% (10-K 2025, MD&A), operating loss widened to $213.9M from $133.4M (10-K 2025, Consolidated Statements of Operations), and operating cash outflow deepened to $42.0M from $38.1M (10-K 2025, Consolidated Statements of Cash Flows). Conversely, the balance sheet improved materially due to $637M of ATM equity issuance and convertible-note conversions: total equity swung from a $3.7M deficit to $611.9M (10-K 2025, Consolidated Balance Sheets), net debt fell to $107.0M from $136.2M (10-K 2025, Note 12), and total liquidity (cash plus AFS investments) rose to $461.5M from $50.1M (10-K 2025, Liquidity and Capital Resources). These opposing forces -- operational decline versus financing-driven balance-sheet repair -- produce a mixed composite trajectory.

2. Red Flags

• Revenue declined 19.3% YoY ($158.2M → $127.7M) while SG&A rose 18.9% ($80.0M → $95.1M), pushing SG&A to 75% of revenue from 51% (10-K 2025, MD&A, Results of Operations).
• Gross margin percentage fell to 22.3% from 28.6% (10-K 2025, Consolidated Statements of Operations).
• Two large non-cash impairments in 2025: $70.6M goodwill (Q2) and $53.4M long-lived intangibles (Q4), totaling $124M (10-K 2025, MD&A, Impairment of long-lived assets / Goodwill impairment).
• Operating cash flow deteriorated for the third consecutive year: -$18.3M (2023) → -$38.1M (2024) → -$42.0M (2025) (10-K 2025, Consolidated Statements of Cash Flows).
• Net loss remained near $294M in both 2024 and 2025 despite $92.8M derivative gains and $13.3M interest income in 2025 (10-K 2025, Consolidated Statements of Operations).
• Non-GAAP Adjusted EBITDA deteriorated sharply: -$2.4M (2024) → -$35.1M (2025) (10-K 2025, Supplemental Non-GAAP Information).
• Shares outstanding increased 73.7% (251.6M → 437.0M) via ATM offerings and warrant/note conversions (10-K 2025, Consolidated Statements of Stockholders' Equity).
• Derivative liabilities remain elevated at $116.9M (10-K 2025, Consolidated Balance Sheets).
• Goodwill impaired in consecutive years ($85.0M in 2024, $70.6M in 2025) and $192.7M new goodwill added from Ask Sage acquisition at year-end 2025 (10-K 2025, Note 8).
• Filing notes "no excess of reporting unit fair value over carrying value" after both 2025 impairments and flags that "any significant adverse changes... could reasonably be expected to negatively affect our key assumptions and may result in future goodwill impairment charges which could be material" (10-K 2025, Note 8).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Overall Assessment -- Revenue fell 19.3% to $127.7M in 2025 from $158.2M in 2024 (10-K 2025, Consolidated Statements of Operations), driven by lower Army program volume and non-recurring 2024 contracts (10-K 2025, MD&A). Gross margin dollars dropped 37.0% to $28.5M, with margin percentage compressing to 22.3% from 28.6% (10-K 2025, Consolidated Statements of Operations). SG&A rose 18.9% to $95.1M (75% of revenue) and R&D increased 54.2% to $16.8M (10-K 2025, MD&A). The company recorded $124.0M of combined goodwill and long-lived asset impairments in 2025 (10-K 2025, MD&A). Operating loss widened 60.3% to $213.9M from $133.4M (10-K 2025, Consolidated Statements of Operations). Net loss held near $294M only because $92.8M derivative gains and $13.3M interest income partially offset the operating deterioration (10-K 2025, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment -- Net cash used in operating activities increased to $42.0M in 2025 from $38.1M in 2024 and $18.3M in 2023 (10-K 2025, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capex) was -$46.3M in 2025 versus -$49.2M in 2024 and -$22.1M in 2023 (10-K 2025, MD&A, Free Cash Flow). Investing cash flow swung to -$606.7M in 2025 due to $229.0M net cash paid for the Ask Sage acquisition and $373.3M net purchases of AFS investments (10-K 2025, Consolidated Statements of Cash Flows). Financing cash flow surged to $691.3M in 2025 from $52.5M in 2024, driven by $628.8M net ATM proceeds and $64.7M warrant exercises (10-K 2025, Consolidated Statements of Cash Flows). Ending cash plus restricted cash rose to $92.6M from $50.1M, but the increase was entirely financing-funded (10-K 2025, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment -- Total equity reversed from a $3.7M deficit to $611.9M positive (10-K 2025, Consolidated Balance Sheets) after 142.3M shares were issued via ATM ($628.8M net proceeds) and convertible notes were converted (10-K 2025, Consolidated Statements of Stockholders' Equity). Total debt (principal) fell to $142.3M from $200.8M, and net debt (less unamortized discount) declined to $107.0M from $136.2M (10-K 2025, Note 12). Total liquidity (cash + AFS investments) increased to $461.5M from $50.1M (10-K 2025, Liquidity and Capital Resources). Derivative liabilities decreased to $116.9M from $170.5M (10-K 2025, Consolidated Balance Sheets). However, goodwill rose to $241.1M from $119.1M due to the $192.7M Ask Sage acquisition, and the company disclosed no excess fair value over carrying value after 2025 impairments (10-K 2025, Note 8).

6. Data Gaps

• Quarterly revenue, margin, and operating loss trends for 2025 and 2026 (10-Qs for Q1-Q3 2025 and Q1-Q2 2026 were referenced but their financial statement details were truncated in the provided filings).
• Quarterly operating and free cash flow for the same periods (same truncation issue).
• Segment-level or contract-type revenue breakdowns beyond the annual customer concentration table (10-K 2025, Note 22).
• Backlog composition changes quarter-over-quarter (only year-end 2024 and 2025 snapshots provided in 10-K 2025, MD&A).
• Detailed covenant compliance metrics for the 2029 Convertible Notes beyond the statement that the company was in compliance as of December 31, 2025 (10-K 2025, Note 12).